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Small regulatory RNAs, such as miRNAs, are increasingly being recognized not only
as regulators of developmental processes but contributors to pathological states. The
number of miRNAs determined experimentally to be involved in Parkinson’s disease (PD)
development and progression is small and includes regulators of pathologic proteins,
neurotrophic factors, and xenobiotic metabolizing enzymes. PD gene-association studies
have also indicated miRNAs in the pathology. In this review, we present known miRNAs
and their validated targets that contribute to PD development and progression. We also
incorporate data mining methods to link additional miRNAs with non-experimentally
validated targets and propose additional roles of miRNAs in neurodegenerative processes.
Furthermore, we present the potential contribution of next-generation-sequencing
approaches to elucidate mechanisms and etiology of PD through discovery of novel
miRNAs and other non-coding RNA classes.
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INTRODUCTION
Parkinson’s disease (PD) is an age-related neurological disorder
with no known cure. It is the second most common neurode-
generative disease and affects 1–2% of the population. The dis-
ease is characterized by resting tremor, bradykinesia, and loss
of dopaminergic neurons (reviewed in Nass and Prezedborski,
2008). The onset in sporadic cases generally occurs between 50
and 60 years of age, yet familial forms can occur at 40 years and
younger. Treatment is typically given with the goal to replace
dopamine (DA) loss through the precursor L-Dopa. Adjuncts
to this therapy include the addition of pharmacologic agents
that decrease the breakdown of DA such as cathechol-O-methyl-
transfer inhibitors andDA agonists.More recent therapies include
grafts of stem cells that replace DA cells and deep brain stimula-
tion, (Arias-Carrión and Salama, 2011; Gibson et al., 2012; Palm
et al., 2012; Weaver et al., 2012). Despite these advances, replace-
ment therapy has remained the standard treatment for PD for
nearly half a century.
The underlying etiology of PD remains elusive; however recent
studies have implicated several genes in the DA neuron pathogen-
esis. α-synuclein (ASYN) has been identified as a major compo-
nent of Lewy bodies, a morphological hallmark of PD (Spillantini
et al., 1997). Genetic studies have also identified several muta-
tions in ASYN as causative for early onset PD through a dominant
mode of inheritance. Other genes found in human genetic studies
linked to PD include: Parkin (PRKN), a ubiquitin ligase asso-
ciated with the ubiquitin-proteosome system; DJ-1, a poorly
characterized anti-oxidant protein; LRRK2, a putative protein
serine threonine kinase; and PINK1, a putative PTEN induced
protein kinase. PRKN is believed to target proteins for degrada-
tion in the proteosome through linkage of ubiquitin molecules
(Tan and Lim, 2005). Mutations in PRKN cause a dysregulation
of proteasome-associated protein degradation that contributes to
DA neuron pathology. DJ-1 regulates oxidation–reduction signal-
ing pathways via induction of gene expression (Bonifati et al.,
2004). DJ-1 has been shown to inhibit DAergic cell death in a cell
and animals models (Jeong et al., 2012; Sun et al., 2012). LRRK2
and PINK1 are both mitochondria kinases. LRRK2 mutations
cause uncoupling of mitochondria in fibroblast and neuroblas-
toma cells (Papkovskaia et al., 2012). PINK-1 is believed to be
involved in mitophagy (Pogson et al., 2011). LRRK2 and PINK-1
may also interact directly or functionally. Finally, at least 16 loci
(PARK1-16) have been associated with the development of PD.
miRNAs are ∼22 nucleotide non-coding RNAs processed by
Drosha and Dicer from larger pri-miRNA (the initial transcript)
and pre-miRNA (the 65–70 nucletide hairpin) (Lee et al., 2006;
Ruby et al., 2006; Asikainen et al., 2007, 2008). miRNAs act to
modulate transcription through the binding of mature miRNAs
(∼22 nucleotide processed form) to RNA-induced silencing com-
plexes (RISC) followed by guidance to target cognate protein cod-
ingmRNAs. ThemiRNAs-RISC complex identifies target proteins
coding mRNAs largely through identification of seed matches
(sequences complementary to positions 2–8 of the miRNA) in
the 3′ untranslated region. miRNAs can operate in tandem,
cooperatively, or without an apparent seed sequence match. The
miRNA-RISC complex then initiates a program for degradation
or block of translation. Endogenous siRNAs are likewise effectors
of gene silencing but are uniquely distinguishable from miRNAs
by having separate biogenesis, amplification, silencing complexes,
targeting, and mode of degradation (Lee et al., 2006; Ruby et al.,
2006; Asikainen et al., 2007, 2008).
Several recent reviews have described a potential role that
miRNAs may have in the development of PD (Gascon and Gao,
2012; Junn andMouradian, 2012; Harraz et al., 2011; Mouradian,
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2012). In this review we will focus on specific miRNAs and their
relationship to PD. We also add studies from model systems to
show the potential interplay between miRNA expression and DA
neuron pathology.
miRNAs IN NEURONAL DEVELOPMENT
Early studies by Ambros and Horvitz defined a role of miRNAs in
C. elegans development (Ambros and Horvitz, 1984). The inves-
tigators identified lin-4 through C. elegans forward genetics as
a small non-coding RNA involved in cell lineage defects. These
studies were elaborated to include an axis of regulatory small
RNAs and their target genes that include lin-14 (Ambros, 1989).
A large number of small RNAs were later cloned, and it was found
that many were primarily expressed in the vertebrate brain (Lee
and Ambros, 2001; Lagos-Quintana et al., 2002). That miRNAs
might be involved in neuronal patterning was later established
through another C.elegans forward genetic study in that identi-
fied lsy-6 (lateral symmetry defective-6) as a miRNA necessary for
left-right neuron asymmetry (Johnston and Hobert, 2003). These
studies were extended to show that miR-273 acts sequentially and
asymmetrically with lsy-6 to confer left/right asymmetric expres-
sion of chemoreceptor genes in C. elegans neurons (Chang et al.,
2004).
miRNAs also play a significant role in vertebrate neuron
development (Sempere et al., 2004; Smirnova et al., 2005). In
higher organisms, forward genetic studies are problematic due
to the long generation times and for large animal population
housing constraints. As a result, sophisticated and imaginative
methods have been developed to identify the role of miRNAs
in brain development. Kim and colleagues identified miR-133b
as critical in midbrain DA neuron development (Kim et al.,
2007). The investigators demonstrated a role for miRNAs in vitro
by conditionally knocking out the Dicer enzyme through Cre-
recombinase transduction in embryonic stem cells just prior
to differentiation of the DA neurons (Kim et al., 2007). Cre-
mediated deletion of Dicer at this stage resulted in nearly com-
plete loss of DA neurons indicating the important role of Dicer
processing of miRNAs (Kim et al., 2007). These findings were
extended in the mouse nervous system using a Cre-recombinase
under the regulation of a DA transporter that led to specific dele-
tion of Dicer in post-mitotic midbrain DA neurons (Kim et al.,
2007). These mice show loss of DAergic neurons and the behav-
ior studies demonstrated reduced locomotion and immobility
similar to human PD. To identify specific miRNAs that could
underlie these affects, quantitative real-time PCR on a panel of
224 miRNAs were assayed and compared to miRNAs from PD
and normal patients. miR-133b showed a significant deficiency in
the midbrain PD relative to controls.
Consistent with the human study, miR-133b was reduced in
two mice models of PD (Pitx3 deficient and 6-OHDA treated)
(de Mena et al., 2010a,b). The authors propose that miR-133b
acts with Pitx3 in a negative feedback circuit that regulates and
maintains midbrain dopaminergic neurons. In order to highlight
the critical role miRNAs play in neuronal specification, Yoo and
colleagues recently reported the conversion of human fibroblasts
into neurons using miR-9/9∗ and miR-124 (Yoo et al., 2011).
This effect was facilitated by NEUROD2. While the converted
cells expressed neuron marker MAP2, and NMDA receptor 1,
single cells did not express dopaminergic/noradrenergic mark-
ers TH or DDC. A broader perspective on the role of specific
miRNAs in the discrete steps involved in neurogenesis was also
recently described (Yang and Shi, 2012). Furthermore, miR-
134 has been identified as a key regulator in development of
dendritic spines in rat hippocampal neurons (Schratt et al.,
2006).
α-SYNUCLEIN CONFERS DA NEURON DEGENERATION
ASYN protofibrils and fibrils accumulate and form protein aggre-
gates in DA neurons and disrupt the proteosomal pathway. The
protein aggregates result in declining cell function and eventu-
ally DA neuronal death leaving behind their Lewy body cores
(Spillantini et al., 1997; Tofaris and Spillantini, 2007). The 3′
untranslated region of ASYN is under regulatory control of miR-7
that is predominantly expressed in neurons (Junn et al., 2009).
miR-7 down-regulates ASYN protects against oxidative stress as
shown in vitro and in mouse models, and normal levels are
decreased in PD suggesting a role for miR-7 in PD pathogenesis
(Junn et al., 2009). These findings were extended with the find-
ing that miR-7 and miR-153 operate additively to reduce levels of
ASYN in brain (Doxakis, 2010). A recent report shows that miR-
7a also acts directly in controlling Pax6 in forebrain, which in turn
specifies a DAergic neuron phenotype (de Chevigny et al., 2012).
This is particularly relevant since it is now widely believed that
neurogenesis occurs in postnatal and adult tissues in the mam-
malian forebrain. Here, neural stem cells separate spacially along
the lateral wall of ventricles and the transcription factor Pax6 is
an important determinant of cells demonstrating the DAergic cell
characteristics. Theoretically, one therapeutic approach to treat
PD may be to target ASYN through miRNAs. A “proof of con-
cept” has already been demonstrated using a miRNA embedded
AAV silencing vector that has been transduced in 293T cells and
PC12 cells (Han et al., 2011). In this case, the miRNA was able to
silence ectopically expressed ASYN suggesting that this approach
is feasible. While these results are promising, future studies will
need to address potential confounders such as the decrease sensi-
tivity to RNA interference in neurons and in immune responses
(Asikainen et al., 2005, 2007; Gehrke et al., 2010; Junn and
Mouradian, 2012).
PROFILING miRNAs IN PD TISSUES AND PD MODELS
In addition to the earlier study involving miR133b (Kim et al.,
2007), other investigators have profiled miRNAs in PD tissues.
Peripheral blood mononucleocytes from 19 patients and 13 con-
trols revealed 18 differentially expressed miRNAs (Martins et al.,
2011). The 622 predicted targets of 11/18 miRNAs were parlayed
with Chip-seq data to converge upon ASYN protein, and the
glycosphingolipid biosynthesis and ubiquitin proteosome path-
ways. A separate miRNA profiling study in human PD brain
tissue of variable pathology found down-regulation of miR-34b/c.
This misregulation was observed in both pre-clinical and clin-
ical stages (Miñones-Moyano et al., 2011). In vitro follow-up
studies that depleted miR-34b/c in SH-SY5Y cells differentiated
to DAergic neurons found decreases in DJ-1 and PARK and
altered mitochondrial function. In a separate study peripheral
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blood was obtained from eight untreated PD patients, seven early
onset PD patients, and eight controls and profiled for 85 dif-
ferent miRNAs by quantitative real time PCR (Margis et al.,
2011). miR-1, miR-22∗, and miR-29 expression distinguished
non-treated PD patients from health subjects, while miR-16-2∗,
miR-26a2∗, and miR30a differentiated treated from untreated
patients.
Consistent with the peripheral blood mononucleocyte study,
whole genome microarray profiling of a C. elegans transgenic
animals overexpressing human ASYN also identified genes in
the uniquitin proteosome pathway that were dysregulated (Lakso
et al., 2003; Vartiainen et al., 2006a,b). miRNA profiling of these
transgenic animals also revealed the down-regulation of seven
and the up-regulation of five miRNAs (Asikainen et al., 2010).
C. elegans animals with a functional mutation in the vesicu-
lar monoamine transporter (VMAT; cat-1 gene) that are unable
to transport DA into synaptic vesicles were also profiled. The
authors found two mRNAs were up-regulated and three down-
regulated. Moreover, the PARK1 mutant C. elegans strain (pdr-1)
was also profiled and two miRNAs were up-regulated while one
was down. miR-64 and miR-65 were co-underexpressed in trans-
genic alphasyunuclein animals and cat-1 strains. In the same
study, ptc-1 which encodes an ortholog of human PTCH, a sterol
sensing domain patched gene, was confirmed as a target of these
miRNAs. let-7 miRNA family members were also observed to be
differentially expressed in human ASYN transgenic animals and
PARK1 (pdr-1) mutants.
PD GENOME-WIDE ASSOCIATION STUDIES (GWAS)
One of the earliest GWAS studies designed to identify miRNAs
linked to PD was based on studies demonstrating that fibrob-
last growth factor 20 (FGF20) is associated with increased risk for
developing PD (Moore et al., 2005). Using a sample size of 1089
affected and 1165 unaffected individuals, the strongest evidence
of association was in a SNP located within the 3′ untranslated
region of FGF20 (Wang et al., 2008). Functional assays were used
to determine that the SNP disrupts a binding site for miR-433.
Thus, the authors were able to identify in a cell system and PD
brain that an increase in translation of FGF20 correlated with
an increase in ASYN. The authors were also able to associate
a SNP site that prevented miRNA activity with PD, and subse-
quent release of inhibition that was concomitant with increased
expression of ASYN. This study provided a novel mechanism
for susceptibility for PD. Unfortunately, linkage of the SNP in
the 3′UTR of FGF20 could not be replicated in a Spanish pop-
ulation of 512 PD patients and 258 healthy controls (de Mena
et al., 2010a) while the original study collected samples from
PD centers in the U.S. In another study, a specific miR-133b
homozygous variation could be found at a higher frequency in
PD patients (6/575) than controls (0/650), but could not be con-
firmed in a second set of patients (1/250) vs. (2/210) controls
(de Mena et al., 2010b). Other GWAS studies have also been dif-
ficult to replicate: an association between polymorphism of miR-
196a2 and PD could not be replicated in a Chinese population
(Haixia et al., 2012); and variants found in the 3′ untranslated
region of SNCA could not affect miR-433 binding (Schmitt et al.,
2012).
BIOINFORMATICS OF miRNAs IN PD
Several bioinformatic tools have been used to integrate knowl-
edge of miRNAs, their targets, and PD. One study has utilized
miRNA target finders to associate key proteins involved in PD
pathology such as ASYN, DJ-1, LRRK2, and PINK1 (Santosh
et al., 2009). Variatas is a useful tool that allows for the retrieval of
disease phenotypes and gene ontology data from public databases
after entering miRNA-associated SNPs (Paananen et al., 2010).
Utilizing another approach, miRo allows the user to enter a
phenotype and returns miRNAs related to the phenotype as
well as their putative targets based on three different algo-
rithms and a list of validated targets (Laganà et al., 2009). For
example, if “Parkinson’s disease” is entered, the list of validated
miRNAs and targets returned are: has-miR-1:BDNF; has-miR-
27b:CYP1B1; has-miR-433:FGF20; miR-124:CYP1B1; has-miR-
1:GCH1; has-miR125b:CYP1A1. Also appearing on the list, but
without validated target are: has-miR-133b:GCH1. The long list
of miRNAs with predicted targets only highlights the difficulty
in validation. As the list of miRNAs linked to PD grows, the
need to identify their targets becomes increasingly important.
The most commonly used tools attempt to identify matches
between the miRNA 6–8 nucleotide “seed regions” with the
putative target gene 3′ untranslated regions and further employ
phylogenetic conservation as an additional criteria (Lall et al.,
2006; Ruby et al., 2006; Hammell, 2010). Another approach uti-
lizes experimental data where miRNAs and their targets have
been immunopreciptated thus providing experimental support
for their predictions (Hammell et al., 2008). Although these
tools identify likely candidates, a common issue is their speci-
ficity. Toward this end, other methods have been successfully
utilized to better predict the putative targets of miRNAs. These
include the use of a supervised machine-learning algorithm
involving a naive Baysian classifer (Yousef et al., 2007). A naive
Bayes classifier is a simple probabilistic classifier with strong
independence assumptions. This is well suited for miRNA tar-
get identification, where factors such as length of the seed
sequence, first nucleotide, and non-seed matches are considered
independent of each other. Another intelligent method utilized
is self-organizing maps, a semisupervised clustering alogrithm
(Heikkinen et al., 2011). Self-organizing maps are artificial neu-
ral networks trained using unsupervised learning to generate
clusters of data. In the application for identifying miRNA tar-
gets in C. elegans, all 3′ UTRs in the nematode were utilized for
training and building the map, and validated and unvalidated
miRNAs where then classified onto the map. The performance
of SOM were benchmarked against existing tools and shown to
outperform all other algorithms, some significantly by correctly
locating the target (classifying) 18/20 experimentally validated
miRNAs.
A table summarizing miRNAs, their putative target, and bio-
logical process linked to PD is shown as Table 1.
NEXT GENERATION SEQUENCING TECHNOLOGIES
The ability to perform massively Sanger sequencing in paral-
lel has given rise to next-generation sequencing technologies
(Hutchison, 2007; Tucker et al., 2009). On commercial plat-
forms such Illumina HiSeq, Applied Bioscience Solid, and Life
www.frontiersin.org January 2013 | Volume 3 | Article 315 | 3
Wong and Nass miRNAs in PD
Table 1 | Summary of miRNAs linked to Parkinson’s disease.
miRNA Putative target Biological process or origin References
miR-133b Pitx3 dopaminergic neuron development Kim et al., 2007
miR-9/9*, miR-124 Multiple neuron specification Yoo et al., 2011
miR-7, miR-153 ASYN gene regulation Junn et al., 2009; Doxakis, 2010
miR-7a Pax6 dopaminergic neuron development de Chevigny et al., 2012
miR-34b/c Unknown PD pathology Miñones-Moyano et al., 2011
miR-1, miR-22*, miR-29 Multiple blood diagnostics, PD vs. healthy Margis et al., 2011
miR-16-2*, miR-26a2*, miR30a Multiple blood diagnostics, PD treated vs. PD untreated Margis et al., 2011
miR-132, miR-134 families Multiple blood diagnostics, mild cognitive impairment Sheinerman et al., 2012
miR-64, miR-65 ptc-1 PD models in C. elegans Asikainen et al., 2010
let-7 Multiple PD models in C. elegans Asikainen et al., 2010
miR-433 FGF20 neuronal maturation, GWAS Moore et al., 2005; Wang et al., 2008
miR-1, miR-27b, miR-433, miR-124,
miR-1, miR-125b
Multiple miRO database Laganà et al., 2009
Technologies Ion Torrent semiconductor sequencing, it is possi-
ble to obtain up to 600 Gb of sequence data per run. This rate
of sequencing has significant implications on the ability to detect
miRNAs in PD tissues, identify variants in miRNA sequences or
their target sites, and to associate loci that increase the risk for PD.
These technologies have been used to both identify novel miRNAs
as well as new siRNA classes in model systems (Lee et al., 2006;
Ruby et al., 2006; Asikainen et al., 2008). One recently discovered
siRNA class termed long non-coding RNA (lncRNA) has >1000
members and nearly half are expressed in specific brain regions in
mice (Mercer et al., 2008, 2009). A hint that lncRNAs could influ-
ence the course of PD has been suggested by the regulation of a
splice variant of PINK1 by a lncRNA (Scheele et al., 2007).While a
definitive impact of lncRNAs on PD pathogenic processes remains
to be seen, such an impact of lncRNAs has already been reported
in Alzheimer’s disease (AD), through an antisense transcript of
β-site amyloid precursor protein-cleaving enzyme (Faghihi et al.,
2008). Other neurodegenerative disorder processes affected by
lncRNAs include Huntington’s disease (HD), amyotrophic lat-
eral sclerosis (ALS), and spinocerebellar ataxia (Qureshi et al.,
2010).
Furthermore, while it has been postulated to utilize miRNA
profiles from blood to elucidate associations with PD (Margis
et al., 2011), it is now technically feasible and affordable to
explore associations between any nucleic acid (DNA or RNA)
and PD. These associations would be highly useful as diagnos-
tic biomarkers, as well as for general studies in understanding
the etiology of PD. As an example, a pair of miRNA families,
miR-132 and miR-134, have been recently studied as plasma
markers of future mild cognitive impairment, a harbinger of AD
or PD (Sheinerman et al., 2012). Moreover, the use of exosomes,
secreted microvesicles available from cell culture media or iso-
lated from the circulation of large animals, as sources of nucleic
acid for diagnostics has gained feasibility due to NGS technolo-
gies (De Smaele et al., 2010). Next-generation sequencing has also
been used to identify methylation differences in the 5′ promoter
regions and first intron of ASYN from different brain regions
of PD patients and compared to controls (de Boni et al., 2011).
Their studies were able to identify differences in methylation
during the later stages of Lewy body diseases. A recent report has
also utilized next-generation sequencing technologies to identify
a rare mutation linked to PD in a Swiss family (Vilariño-Güell
et al., 2011). The high throughput of NGS technologies has also
lead to a 1000 human genomes project, which has provided bet-
ter quality human sequence maps with enriched information on
SNP location and frequencies, as well as occurrences of indels
and gene duplications (1000 Genomes Project Consortium et al.,
2012). These data will be highly useful in mapping risk factors for
sporadic PD.
Lastly, the long awaited ENCODE project, that had an auda-
cious goal of identifying all the functional elements of the human
genome has recently been completed (Ecker et al., 2012). The data
is free and available for immediate use. This practicallymeans that
every PD-associated gene known to date and those to be identified
in the future will have a wealth of basic functional information
available concerning it at the genome level. Moreover, with the
modENCODE project, parallel orthologous functional genomic
data will be available as well from D. melanogaster and C. elegans
(Muers, 2011).
CONCLUSIONS
It is abundantly clear that we are in the early days of under-
standing, identifying, and realizing the potential of manipulating
miRNA levels in the treatment of PD. Novel stem cell methodolo-
gies involving the use of miRNAs have given rise to the possibility
of replacing lost dopaminergic cells and changing the current
paradigms of treatment. Together with next generation sequenc-
ing technologies and associated bioinformatics development, the
application of knowledge regarding miRNAs and neuronal mat-
uration should lead to exciting new discoveries and eventually
effective therapies.
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